Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)

• Status: Recruiting
• Trial end date: 2024-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to describe safety and efficacy of Dapaglifozin in adults patients with a systemic right ventricle (congenitally corrected transposition of the great arteries or transposition of the great arteries following arterial switch procedure) and impaired systolic function of the systemic right ventricle.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Monaldi Hospital
• Treatments: Dapagliflozin

Criteria

Inclusion Criteria:

• Age≥18years

• Optimal medical therapy or at least 3months

• Systemic right ventricle ejection fraction≤40%, assessed on echocardiography

Exclusion Criteria:

• Univentricular physiology

• Systolic blood pressure<90mmHg

• Glomerular filtration rate(GFR)<30ml/min